6/13 -
Tirasemtiv May Slow Respiratory Decline in ALS
Results of a large-scale trial of tirasemtiv in ALS show the drug may slow respiratory decline without improving scores on the ALS Functional Rating Scale
Posted on Thursday, May 1, 2014 - 14:07, By: Margaret Wahl
The experimental drug tirasemtiv, in development by South San Francisco biopharmaceutical company Cyokinetics as a potential treatment for amyotrophic lateral sclerosis (ALS), slowed the decline in at least one measure of respiratory function in a recent, large-scale study known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS).